The U.S. Food and Drug Administration (FDA) issued a warning that veterinarians and pet owners should be alert for any unusual pet behavior in connection to recalled eyedrops.
In a notice posted on March 13, the FDA’s division on veterinary medicine said that certain recalled eyedrops could cause eye infections in animals. The agency said the products were sold under a number of different brands and were marketed for use in people.
It noted that it has received at least one adverse event report in an animal in connection to the eye drops.
“Veterinary hospitals and pet owners should check their eye drops against the brands and lots listed here and discard any products that are included in the recalls,” the federal regulator added.
Pet owners who have given the products to their animals should take note if their pets are “rubbing or scratching at their eyes or have swelling or discharge of the eyes,” the FDA said. If so, they should consult their veterinarians immediately, it added.
“Testing was not able to conclusively prove that the eye drops caused the infection. Pet owners who have used these products on their pets and notice that the pets are rubbing or scratching at their eyes or have swelling or discharge of the eyes should consult their veterinarians immediately,” the spokesperson told the outlet.
“These products are intended to be sterile. Ophthalmic drug products pose a potential heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses,” the FDA says.
The agency said that people who have symptoms of an eye infection in connection to an eye drop product should speak to a health care provider or seek medical care immediately. The FDA has recommended that people discard the eye drops and seek a refund.
Earlier in 2023, federal officials linked an outbreak of drug-resistant bacteria to eyedrops from two companies, EzriCare and Delsam Pharma. Dozens of people in the U.S. tested positive for eye infections from the rare bacterial strain, according to the Centers for Disease Control and Prevention (CDC).
After the products were recalled in February, health inspectors visited the manufacturing plant in India that made the eyedrops and uncovered problems with how they were made and tested, including inadequate sterility measures.
An October recall of two dozen eyedrop brands came after FDA staff found cracked floors, barefoot workers, and other unsanitary conditions at a Mumbai plant that supplied products to CVS, Walmart, and other major retailers. It was the first time FDA staff had visited the site.
